KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 1 filers reported holding KINNATE BIOPHARMA INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 6.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $708 | -30.9% | 505,956 | +49.8% | 0.00% | 0.0% |
| Q2 2023 | $1,024 | +48.2% | 337,800 | +205.7% | 0.00% | 0.0% |
| Q1 2023 | $691 | +9.5% | 110,500 | +6.9% | 0.00% | 0.0% |
| Q4 2022 | $631 | -99.9% | 103,400 | +2.9% | 0.00% | -50.0% |
| Q3 2022 | $1,201,000 | -0.4% | 100,500 | +5.1% | 0.00% | +100.0% |
| Q2 2022 | $1,206,000 | +348.3% | 95,600 | +300.0% | 0.00% | – |
| Q1 2022 | $269,000 | -50.0% | 23,900 | +2.3% | 0.00% | -100.0% |
| Q3 2021 | $538,000 | -35.6% | 23,358 | -34.9% | 0.00% | 0.0% |
| Q2 2021 | $836,000 | – | 35,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $58,997,022 | 25.20% |
| Vida Ventures Advisors, LLC | 2,207,772 | $13,467,409 | 18.10% |
| Lynx1 Capital Management LP | 1,998,417 | $12,190,344 | 10.54% |
| Nextech Invest Ltd. | 2,329,480 | $14,209,828 | 5.65% |
| Foresite Capital Management V, LLC | 875,001 | $5,337,506 | 4.15% |
| RA Capital Management | 4,264,144 | $26,011,278 | 0.53% |
| Orbimed Advisors | 4,043,629 | $24,666,137 | 0.47% |
| SVB FINANCIAL GROUP | 23,382 | $142,630 | 0.39% |
| HARVARD MANAGEMENT CO INC | 498,001 | $3,037,806 | 0.38% |
| Novo Holdings A/S | 815,707 | $4,975,813 | 0.31% |